What is Wedbush's Forecast for APLS FY2025 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush raised their FY2025 earnings per share estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.16) for the year, up from their previous estimate of ($0.22). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.52) EPS.

APLS has been the topic of a number of other research reports. Citigroup reduced their price target on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a report on Thursday, May 22nd. Morgan Stanley boosted their price target on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an "equal weight" rating in a report on Wednesday, July 2nd. Bank of America boosted their price target on Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a "neutral" rating in a report on Wednesday. Cantor Fitzgerald assumed coverage on Apellis Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $44.00 price target on the stock. Finally, Royal Bank Of Canada reduced their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a report on Thursday, May 8th. Nine equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $40.00.

Apellis Pharmaceuticals Trading Down 2.8%

Shares of APLS traded down $0.57 during trading hours on Thursday, hitting $19.47. The company had a trading volume of 1,842,831 shares, compared to its average volume of 2,375,401. The firm has a market cap of $2.45 billion, a P/E ratio of -10.88 and a beta of 0.67. The stock's 50 day moving average price is $18.23 and its 200 day moving average price is $22.50. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $41.94.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The company's revenue for the quarter was down 3.2% on a year-over-year basis. During the same period last year, the firm earned ($0.54) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas raised its position in shares of Apellis Pharmaceuticals by 9.4% in the fourth quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock worth $691,000 after acquiring an additional 1,864 shares during the period. Ameriprise Financial Inc. raised its position in shares of Apellis Pharmaceuticals by 2.6% in the fourth quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company's stock worth $28,170,000 after acquiring an additional 22,507 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Apellis Pharmaceuticals by 147.8% in the first quarter. Assenagon Asset Management S.A. now owns 74,325 shares of the company's stock worth $1,625,000 after acquiring an additional 44,332 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Apellis Pharmaceuticals by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company's stock worth $6,793,000 after purchasing an additional 21,822 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Apellis Pharmaceuticals by 1,795.4% during the first quarter. GAMMA Investing LLC now owns 10,235 shares of the company's stock worth $224,000 after purchasing an additional 9,695 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $19.55, for a total transaction of $97,750.00. Following the transaction, the general counsel directly owned 128,730 shares of the company's stock, valued at $2,516,671.50. This trade represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Cedric Francois sold 19,725 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $20.21, for a total transaction of $398,642.25. Following the transaction, the chief executive officer directly owned 331,605 shares in the company, valued at approximately $6,701,737.05. The trade was a 5.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 169,090 shares of company stock worth $3,403,832 over the last three months. 6.80% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).